Literature DB >> 23788268

Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?

Michael Weller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23788268      PMCID： PMC3688025          DOI： 10.1093/neuonc/not095

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.

Authors:  M Weller; T Gorlia; J G Cairncross; M J van den Bent; W Mason; K Belanger; A A Brandes; U Bogdahn; D R Macdonald; P Forsyth; A O Rossetti; D Lacombe; R-O Mirimanoff; C J Vecht; R Stupp
Journal:  Neurology       Date:  2011-08-31       Impact factor: 9.910

Review 2.  Epilepsy meets cancer: when, why, and what to do about it?

Authors:  Michael Weller; Roger Stupp; Wolfgang Wick
Journal:  Lancet Oncol       Date:  2012-09       Impact factor: 41.316

3.  P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy.

Authors:  Stefan Oberndorfer; Maria Piribauer; Christine Marosi; Heinz Lahrmann; Peter Hitzenberger; Wolfgang Grisold
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

4.  Potential role for valproate in the treatment of high--risk brain tumors of childhood-results from a retrospective observational cohort study.

Authors:  Francisco Helder Cavalcante Felix; Nadia Mendonça Trompieri; Orlandira Leite de Araujo; Karine Martins da Trindade; Juvenia Bezerra Fontenele
Journal:  Pediatr Hematol Oncol       Date:  2011-06-24       Impact factor: 1.969

5.  Valproic acid use during radiation therapy for glioblastoma associated with improved survival.

Authors:  Christopher A Barker; Andrew J Bishop; Maria Chang; Kathryn Beal; Timothy A Chan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-20       Impact factor: 7.038

6.  Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.

Authors:  Melissa Kerkhof; Janneke C M Dielemans; Melanie S van Breemen; Hanneke Zwinkels; Robert Walchenbach; Martin J Taphoorn; Charles J Vecht
Journal:  Neuro Oncol       Date:  2013-05-16       Impact factor: 12.300
  6 in total
  5 in total

1.  The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.

Authors:  Abdel Nasser Hosein; Yi Chieh Lim; Bryan Day; Brett Stringer; Stephen Rose; Richard Head; Leah Cosgrove; Peter Sminia; Michael Fay; Jennifer H Martin
Journal:  J Neurooncol       Date:  2015-02-04       Impact factor: 4.130

Review 2.  Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?

Authors:  Michael Fay; Richard Head; Jennifer Martin
Journal:  J Neurooncol       Date:  2015-05-30       Impact factor: 4.130

Review 3.  Medical management of brain tumors and the sequelae of treatment.

Authors:  David Schiff; Eudocia Q Lee; Lakshmi Nayak; Andrew D Norden; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-10-30       Impact factor: 12.300

4.  Molecular dissection of the valproic acid effects on glioma cells.

Authors:  Sabine Hoja; Markus Schulze; Michael Rehli; Martin Proescholdt; Christel Herold-Mende; Peter Hau; Markus J Riemenschneider
Journal:  Oncotarget       Date:  2016-09-27

5.  A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma.

Authors:  Elias A El-Habr; Luiz G Dubois; Fanny Burel-Vandenbos; Alexandra Bogeas; Joanna Lipecka; Laurent Turchi; François-Xavier Lejeune; Paulo Lucas Cerqueira Coehlo; Tomohiro Yamaki; Bryan M Wittmann; Mohamed Fareh; Emna Mahfoudhi; Maxime Janin; Ashwin Narayanan; Ghislaine Morvan-Dubois; Charlotte Schmitt; Maité Verreault; Lisa Oliver; Ariane Sharif; Johan Pallud; Bertrand Devaux; Stéphanie Puget; Penelope Korkolopoulou; Pascale Varlet; Chris Ottolenghi; Isabelle Plo; Vivaldo Moura-Neto; Thierry Virolle; Hervé Chneiweiss; Marie-Pierre Junier
Journal:  Acta Neuropathol       Date:  2016-12-28       Impact factor: 17.088
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.